CVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says

MT Newswires Live

Dec 04, 2025

CVS Health (CVS) is still "long crowded and well-liked" by investors ahead of next week's investor event, amid expectations for upside compared with near- and long-term consensus estimates, UBS said in a note Wednesday.

The investment firm said CVS investors will be eyeing factors like the margin recovery of the company's Health Care Benefits business, the mitigation of potential recontracting risk and rebate guarantee pressure on Caremark, as well as the earnings stabilizations of the company's Pharmacy and Consumer Wellness segment.

"Disappointment on the first two focuses would be negatively received and likely pressure the stock," UBS said.

The investment firm said that there is an expectation that CVS' 2025 guidance will be lifted modestly and that the company's initial 2026 outlook will "likely move up accordingly by a marginal amount," which would be between $0.05 and $0.10.

UBS said it would view this outlook as "conservative" compared with current buy-side estimates, but "enough (given upside seen versus CVS' initial 2025 outlook YTD) for the stock to continue to work into 2026."

UBS has a buy rating on CVS and $96 price target.

Price: 76.58, Change: -1.04, Percent Change: -1.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588600028"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588600028\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588600028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588600028","market":"nz","top_or_hot":-1,"title":"CVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says","media":"MT Newswires Live","content":"<html><body><p> CVS Health (CVS) is still \"long crowded and well-liked\" by investors ahead of next week's investor event, amid expectations for upside compared with near- and long-term consensus estimates, UBS said in a note Wednesday.</p><p>The investment firm said CVS investors will be eyeing factors like the margin recovery of the company's Health Care Benefits business, the mitigation of potential recontracting risk and rebate guarantee pressure on Caremark, as well as the earnings stabilizations of the company's Pharmacy and Consumer Wellness segment.</p><p>\"Disappointment on the first two focuses would be negatively received and likely pressure the stock,\" UBS said.</p><p>The investment firm said that there is an expectation that CVS' 2025 guidance will be lifted modestly and that the company's initial 2026 outlook will \"likely move up accordingly by a marginal amount,\" which would be between $0.05 and $0.10.</p><p>UBS said it would view this outlook as \"conservative\" compared with current buy-side estimates, but \"enough (given upside seen versus CVS' initial 2025 outlook YTD) for the stock to continue to work into 2026.\"</p><p>UBS has a buy rating on CVS and $96 price target.</p><p>Price: 76.58, Change: -1.04, Percent Change: -1.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-04 00:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CVS Health (CVS) is still \"long crowded and well-liked\" by investors ahead of next week's investor event, amid expectations for upside compared with near- and long-term consensus estimates, UBS said in a note Wednesday.</p><p>The investment firm said CVS investors will be eyeing factors like the margin recovery of the company's Health Care Benefits business, the mitigation of potential recontracting risk and rebate guarantee pressure on Caremark, as well as the earnings stabilizations of the company's Pharmacy and Consumer Wellness segment.</p><p>\"Disappointment on the first two focuses would be negatively received and likely pressure the stock,\" UBS said.</p><p>The investment firm said that there is an expectation that CVS' 2025 guidance will be lifted modestly and that the company's initial 2026 outlook will \"likely move up accordingly by a marginal amount,\" which would be between $0.05 and $0.10.</p><p>UBS said it would view this outlook as \"conservative\" compared with current buy-side estimates, but \"enough (given upside seen versus CVS' initial 2025 outlook YTD) for the stock to continue to work into 2026.\"</p><p>UBS has a buy rating on CVS and $96 price target.</p><p>Price: 76.58, Change: -1.04, Percent Change: -1.34</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1059921491.USD","symbol_name":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588600028","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588600028","pubTimestamp":1764779067,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CVS Health  is still \"long crowded and well-liked\" by investors ahead of next week's investor event, amid expectations for upside compared with near- and long-term consensus estimates, UBS said in a note Wednesday.The investment firm said CVS investors will be eyeing factors like the margin recovery of the company's Health Care Benefits business, the mitigation of potential recontracting risk and rebate guarantee pressure on Caremark, as well as the earnings stabilizations of the company's Pharmacy and Consumer Wellness segment.\"Disappointment on the first two focuses would be negatively received and likely pressure the stock,\" UBS said.The investment firm said that there is an expectation that CVS' 2025 guidance will be lifted modestly and that the company's initial 2026 outlook will \"likely move up accordingly by a marginal amount,\" which would be between $0.05 and $0.10.UBS said it would view this outlook as \"conservative\" compared with current buy-side estimates, but \"enough  for t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","CVS":"西维斯健康","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4585":"ETF&股票定投概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4504":"桥水持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4550":"红杉资本持仓","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","CVS.AU":"Cervantes Corp Ltd","BK4196":"保健护理服务","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4581":"高盛持仓"},"translate_title":"瑞银表示，CVS Health长期以来仍然拥挤，在投资者对上涨的预期中很受欢迎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS.AU":1,"CVS":1.5},"content_text":"CVS Health (CVS) is still \"long crowded and well-liked\" by investors ahead of next week's investor event, amid expectations for upside compared with near- and long-term consensus estimates, UBS said in a note Wednesday.The investment firm said CVS investors will be eyeing factors like the margin recovery of the company's Health Care Benefits business, the mitigation of potential recontracting risk and rebate guarantee pressure on Caremark, as well as the earnings stabilizations of the company's Pharmacy and Consumer Wellness segment.\"Disappointment on the first two focuses would be negatively received and likely pressure the stock,\" UBS said.The investment firm said that there is an expectation that CVS' 2025 guidance will be lifted modestly and that the company's initial 2026 outlook will \"likely move up accordingly by a marginal amount,\" which would be between $0.05 and $0.10.UBS said it would view this outlook as \"conservative\" compared with current buy-side estimates, but \"enough (given upside seen versus CVS' initial 2025 outlook YTD) for the stock to continue to work into 2026.\"UBS has a buy rating on CVS and $96 price target.Price: 76.58, Change: -1.04, Percent Change: -1.34","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}